Dr. Robert Stark
No Impact of Body Mass Index on Outcome in Stroke Patients Treated with IV Thrombolysis BMI and IV Thrombolysis Outcome
Branscheidt M, Luft A, Wegener S, Held U, Wertli M, Arnold M, Jung S, Fischer U, Stark R, Kägi G, Eskioglou E, Michel P, Schneider J, Sarikaya H. No Impact of Body Mass Index on Outcome in Stroke Patients Treated with IV Thrombolysis BMI and IV Thrombolysis Outcome. PloS one 2016; 11:e0164413.
Oct 11, 2016No Impact of Body Mass Index on Outcome in Stroke Patients Treated with IV Thrombolysis BMI and IV Thrombolysis Outcome
Oct 11, 2016PloS one 2016; 11:e0164413
Branscheidt Meret, Luft Andreas, Wegener Susanne, Held Ulrike, Wertli Maria, Arnold Marcel, Jung Simon, Fischer Urs, Stark Robert, Kägi Georg, Eskioglou Elissavet, Michel Patrik, Schneider Juliane, Sarikaya Hakan
Matching genetic and clinical information - a new spastin mutation causing HSP4 and a new non-pathogenic epsilon sarcoglycan mutation in one patient
Stark R, Felbecker A (2016). Matching genetic and clinical information - a new spastin mutation causing HSP4 and a new non-pathogenic epsilon sarcoglycan mutation in one patient.
Jun 13, 2016Matching genetic and clinical information - a new spastin mutation causing HSP4 and a new non-pathogenic epsilon sarcoglycan mutation in one patient
Jun 13, 2016EAN
Stark Robert, Felbecker Ansgar
The clinical spectrum of PARKIN disease (PARK 2) and heterozygous gene mutation carriers
Walch J, Kägi G, Tettenborn B, Stark R (2015). The clinical spectrum of PARKIN disease (PARK 2) and heterozygous gene mutation carriers.
Jun 18, 2015The clinical spectrum of PARKIN disease (PARK 2) and heterozygous gene mutation carriers
Jun 18, 201519th International Congress of Parkinson´s disease and Movement Disorders
Walch Julia, Kägi Georg, Tettenborn Barbara, Stark Robert